Health & Fitness
Health and Fitness
Health and Fitness
Fri, August 6, 2010
[ Fri, Aug 06th 2010
] - Market Wire
[ Fri, Aug 06th 2010
] - Market Wire
[ Fri, Aug 06th 2010
] - Market Wire
[ Fri, Aug 06th 2010
] - Market Wire
[ Fri, Aug 06th 2010
] - Market Wire
[ Fri, Aug 06th 2010
] - Market Wire
Thu, August 5, 2010
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
[ Thu, Aug 05th 2010
] - Market Wire
YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
- Potent, oral JAK1/2 inhibitor - Excellent selectivity against a panel of over 150 structurally diverse protein kinases - Excellent preclinical safety profile - Direct preclinical comparison with other JAK2 inhibitors indicates that very few of the other compounds in development match the potency and selectivity of CYT387.
Contributing Sources
